Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Reply to Weinberger.
Journal: American journal of respiratory and critical care medicine
Published: April 27, 2023
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Journal: American journal of respiratory and critical care medicine
Published: March 30, 2023
Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).
Journal: Rheumatology (Oxford, England)
Published: December 13, 2022
Alcohol-associated Liver Disease Is Now the Most Common Indication for Liver Transplant Waitlisting Among Young American Adults.
Journal: Transplantation
Published: June 01, 2022
Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
Journal: European journal of gastroenterology & hepatology
Published: April 12, 2022
Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension.
Journal: Rheumatology (Oxford, England)
Published: January 26, 2021
Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab.
Journal: Inflammatory bowel diseases
Published: July 24, 2020
Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data.
Journal: PloS one
Published: October 04, 2019
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
Journal: Therapeutic advances in gastroenterology
Published: April 24, 2019
Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
Journal: Journal of Crohn's & colitis
Published: March 09, 2019
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Journal: Journal of Crohn's & colitis
Published: February 28, 2019
Last Updated: 09/26/2026